Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relaps...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The lancet oncology 2021-03, Vol.22 (3), p.e105-e118
Hauptverfasser: Moreau, Philippe, Kumar, Shaji K, San Miguel, Jesús, Davies, Faith, Zamagni, Elena, Bahlis, Nizar, Ludwig, Heinz, Mikhael, Joseph, Terpos, Evangelos, Schjesvold, Fredrik, Martin, Thomas, Yong, Kwee, Durie, Brian G M, Facon, Thierry, Jurczyszyn, Artur, Sidana, Surbhi, Raje, Noopur, van de Donk, Niels, Lonial, Sagar, Cavo, Michele, Kristinsson, Sigurdur Y, Lentzsch, Suzanne, Hajek, Roman, Anderson, Kenneth C, João, Cristina, Einsele, Hermann, Sonneveld, Pieter, Engelhardt, Monika, Fonseca, Rafael, Vangsted, Annette, Weisel, Katja, Baz, Rachid, Hungria, Vania, Berdeja, Jesus G, Leal da Costa, Fernando, Maiolino, Angelo, Waage, Anders, Vesole, David H, Ocio, Enrique M, Quach, Hang, Driessen, Christoph, Bladé, Joan, Leleu, Xavier, Riva, Eloisa, Bergsagel, Peter Leif, Hou, Jian, Chng, Wee Joo, Mellqvist, Ulf-Henrik, Dytfeld, Dominik, Harousseau, Jean-Luc, Goldschmidt, Hartmut, Laubach, Jacob, Munshi, Nikhil C, Gay, Francesca, Beksac, Meral, Costa, Luciano J, Kaiser, Martin, Hari, Parameswaran, Boccadoro, Mario, Usmani, Saad Z, Zweegman, Sonja, Holstein, Sarah, Sezer, Orhan, Harrison, Simon, Nahi, Hareth, Cook, Gordon, Mateos, Maria-Victoria, Rajkumar, S Vincent, Dimopoulos, Meletios A, Richardson, Paul G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(20)30756-7